[ET Net News Agency, 2 September 2021] CSPC Pharmaceutical Group Limited (01093) said
the "Oseltamivir Phosphate Capsules (75mg)" developed by CSPC Ouyi Pharmaceutical Co.,
Ltd., a subsidiary of the company, has obtained drug registration approval granted by the
National Medical Products Administration of the People's Republic of China, and is deemed
to have passed the consistency of quality and efficacy evaluation of generic drugs.
Oseltamivir is a selective inhibitor of influenza virus neuraminidase, which can inhibit
the release of virus from infected cells and reduce the spread of influenza A or B viruses
via inhibition of neuraminidase activity of influenza A and B viruses. The product is
indicated for the treatment of influenza A and B in adults and children aged 1 year or
above, and prevention of influenza A and B in adults and adolescents aged 13 years or
above. (RC)
|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
01093 CSPC PHARMA
Nominal 
5.810 -0.060 (-1.022%) Others
02/09/2021 14:13
CSPC Pharma (01093) gets drug registration approval
| Remark: | Real time quote last updated: 16/04/2024 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service |